Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a research partnership with Evive Biotech Ltd, a subsidiary of Chinese pharmaceutical company Yifan Pharmaceutical Co., Ltd (SHE: 002019). The collaboration will utilize Nona’s antibody technology platform, Harbour Mice, to focus on the discovery of dual and double light chain (H2L2) antibodies. Financial details of the agreement have not been disclosed.
Nona Bio is a global biotechnology company dedicated to innovative technology and offers a comprehensive solution from “Idea to IND” (I to I), encompassing target validation, antibody discovery, and preclinical research. Evive Biotech, on the other hand, has a business presence spanning the United States, Singapore, and China.- Flcube.com
